Dongna Investment Strategically Invests in Fibronectin Biotech to Break Global Supply Bottleneck

VCBeat has learned that Dongna Medical and Health Fund, under Guangdong Dongna Private Equity Fund Management Co., Ltd. (hereinafter referred to as “Dongna Investment”), has recently completed a strategic investment in Guangzhou Fibronectin Biotechnology Co., Ltd. (hereinafter referred to as “Fibronectin Biotech”). This round of financing will accelerate the commercialization of Fibronectin Biotech’s globally unique industrialization platform for animal-derived full-structure fibronectin (FN), deepen its presence in biopharmaceuticals, high-end medical devices, and functional skincare, and jointly promote the innovation and translation of regenerative medicine technologies.

Fibronectin Biotech was founded by Professor Wang Deliang, Professor Zhang Junying, and Wang Haoqing, the third-generation inheritor of the joint production patent technology for fibronectin. It is a high-tech biopharmaceutical company dedicated to industrial development based on independent intellectual property rights. Centered on its fully proprietary patented technology for fibronectin, the company is the only enterprise globally to achieve large-scale, continuous industrial production of full-structure plasma fibronectin of animal origin. Its proprietary “Joint Production Process for Animal Blood Fibronectin” enables the extraction of multiple high-value active proteins—including fibronectin, immunoglobulins, albumin, and superoxide dismutase—from a single raw material, thereby realizing an efficient biomanufacturing model characterized by “multiple products from one source.”

Built upon four decades of research accumulated by three generations of professors—spanning our grandparents’ and parents’ generations—and steadfast in the original mission of “commercializing laboratory research to empower and enhance quality of life,” Fibronectin Biotech has possessed dual advantages in technological innovation and commercial implementation since its inception. This has enabled the company to rapidly and efficiently deliver higher-dimensional, immediate-efficacy solutions to the regenerative medicine market.

Fibron Biotech is positioned atResearch and Development and Manufacturing of Core Raw Materials for High-End Biomaterials, focusing on the translational application of fibronectin across the entire spectrum of regenerative medicine and aesthetic regeneration. The company’s product pipeline encompasses biomedical raw materials, cosmetic-grade skincare products, and medical devices under development, establishing a hybrid business model characterized by “exclusive upstream patented raw material technologies plus diversified midstream application outputs.”

The company’s strategic objectives are clearly defined: in the short term, it will leverage B2B raw material sales and technical services to consolidate its leading position in the cosmetics and medical aesthetics markets; in the medium term, it will use the acquisition of regulatory approvals for fibronectin-related medical devices as a catalyst to formally enter high-value medical markets such as chronic wound repair; and in the long term, it will expand into the international biopharmaceutical market, achieving global commercialization of fibronectin-based biopharmaceutical products for multiple indications.

High technical barriers and strong scarcity of core technologies:The only enterprise in China possessing a bio-integrated co-production process, capable of delivering high-quality, efficient, and stable large-scale supply of natural full-structure fibronectin and active proteins.

The World's Only Industrialization Capability: Breaking through the bottleneck of laboratory-grade reagents, addressing the long-standing global pain points of unstable fibronectin supply and high costs, and achieving "domestic substitution for imports" of key biomaterials.

Profound Technical and Clinical Expertise: The technology has been passed down and iterated over three generations spanning nearly 40 years, establishing a comprehensive barrier of independent intellectual property rights. It has secured India’s first FN approval and accumulated clinical case data from over 5,000 patients, with a healing efficacy rate as high as 98.7%. This provides strong support for the success rate of clinical trials in product pipeline design and demonstrates product effectiveness.

Safety and Compliance Advantages Highlighted:Possesses a valid CAS number, has passed the comprehensive safety assessment, and maintains a three-year record of safe usage.

A Vast Market on the Verge of an Explosion: As a core functional protein of the extracellular matrix, fibronectin has extremely extensive downstream applications. It is not only the optimal alternative to the banned EGF (Epidermal Growth Factor) with significant market potential in the efficacy-based skincare sector, but also represents a blue-ocean market for the treatment of chronic non-healing wounds (such as diabetic foot ulcers and pressure injuries). Currently, no domestically produced Class III medical device products of this kind have been approved in China.

Lou Kaiyan, Partner at Dongna Investment, stated: "Fibronectin is a core functional protein of the extracellular matrix and plays an irreplaceable role in wound repair, tissue regeneration, and the functionalization of biomaterials. As the sole manufacturer to achieve industrial-scale production of animal-derived full-structure fibronectin, Fibronectin Bio retains multiple functional domains, offering further potential for exploration in the field of tissue regeneration and repair. In particular, full-structure fibronectin has demonstrated significant promise in the treatment of acute and chronic wounds, the prevention and treatment of gynecological, ophthalmic, dental, and oral diseases, as well as in the fields of aesthetics and healthcare. Through this investment, we aim to accelerate Fibronectin Bio’s launch of clinical-grade products to address the genuine needs of patients with refractory wounds, while also driving the company’s industrial upgrading and providing new raw material solutions for the medical aesthetics, medical, and broader health industries."

Dongna Investment’s strategic investment in Fibronectin Biologics is grounded in its deep recognition of the company’s proprietary technologies, scarce industrialization capabilities, and substantial market potential. Leveraging Fibronectin Biologics’ solid scientific foundation and clear development roadmap, combined with the capital and industrial resources provided by Dongna Investment, both parties will join forces to accelerate the industrialization and commercialization of this domestically developed, original biomaterial. This collaboration aims not only to create commercial value but also to make positive contributions to advancing China’s regenerative medicine industry and addressing unmet clinical needs. Looking ahead, Dongna Investment will continue to accompany and support the growth of Fibronectin Biologics, working together to realize the industrial vision of “Chinese Ingredients, Global Value.”

Guangdong Dongna Private Equity Fund Management Co., Ltd. was established in 2023 and is one of the first professional institutions licensed to operate under China’s new regulations for private equity funds. The company is committed to becoming a novel equity investment firm that integrates incubation capabilities, investment management expertise, and M&A integration. Currently, its investment focus centers on two key sectors: biopharmaceuticals and vertical AI applications. Dongna Investment consistently upholds a passion for technological innovation, respect for market dynamics, and deep engagement in industrial convergence. Using capital as its vessel and value as its compass, the firm strives to support visionary founders, transforming each investment into solid economic value and profound social impact.

In terms of core sector deployment, the company’s Dongna Medical Health Fund focuses intensively on four key areas: innovative medical devices for import substitution, regenerative medicine related to cell therapy, diagnosis and treatment of chronic and degenerative diseases, and AI-driven pharmaceutical innovation. The fund makes precise investments in technological innovations that fill medical gaps and transform traditional healthcare practices. Leveraging resources from diverse capital partners, including government-guided funds and listed companies, the company has built a comprehensive industrial resource network covering tertiary hospitals, primary healthcare institutions, OTC channels, and overseas markets. This network provides portfolio companies with all-around empowerment services, including clinical demand assessment, market channel expansion, strategic layout planning, technology incubation acceleration, and financing and M&A matchmaking, thereby helping enterprises shorten R&D cycles and accelerate industrial commercialization.